Results 11 to 20 of about 454 (136)

Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations. [PDF]

Anal Cell Pathol (Amst), 2021
Chronic myeloid leukemia (CML) is a disease of hematopoietic stem cells and is caused by the balanced translocations among the long arms of chromosomes 9 and 22, which are called the Philadelphia (Ph) chromosome. In this study, 131 CML patients were enrolled.
Asif M, Hussain A, Wali A, Ahmed N, Ali I, Iqbal Z, Amir M, Shafiq M, Rasool M.   +8 more
europepmc   +2 more sources

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors [PDF]

Ann Oncol, 2016
Adenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families including cKIT.
Argiris,, Cohen,, Cullen,, Gilbert,, Hayes,, Karrison,, Kies,, Lenz,, Lim,, Razak,, Roberts,, Saba,, Takebe,, Tanvetyanon,, Vokes,, Wong, Stuart J., Worden,   +16 more
core   +3 more sources

Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion [PDF]

Mol Cancer, 2017
A Gerrits, AH Elmaagacli, Andreas Dahl, Boris Fehse, C Lu, C Zhao, D Hanahan, D Kirchner, DG Gibson, DJ Barnes, Doreen Winkelmann, DS Krause, DS Krause, F Caiado, G Yu, GL Klement, GQ Daley, GQ Daley, HE Bhang, I Glauche, I Roeder, I Roeder, I Roeder, Ingmar Glauche, Ingo Roeder, J Gabert, J McLaughlin, JV Melo, JY Reuther, K Cornils, K Cornils, K Cornils, K Klauke, K Schepers, K Schepers, Kerstin Cornils, L Biasco, L Thielecke, Lars Thielecke, M Braig, M Hamdane, M Hildinger, M Horn, M Horn, M Kanehisa, M Spielmann, Mathias Lesche, MW Huston, MW Pfaffl, OS Kustikova, OS Kustikova, OS Kustikova, R Kumar, R Palacios, R Ren, S Anders, S Newrzela, SH Naik, SJ Stein, SN Porter, TD Wu, Tim Aranyossy, X Jiang, X Jiang, Y Liao   +64 more
core   +2 more sources

Steered Molecular Dynamics Simulations Study on FABP4 Inhibitors [PDF]

Molecules, 2023
Crocetti, Letizia
core   +2 more sources

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML [PDF]

, 2012
Occurrence of the BCR-ABL[superscript T315I] gatekeeper mutation is among the most pressing challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors have multiple targets and pleiotropic effects that could be exploited for ...
A Quintás-Cardama, A Seth, A Subramanian, AA Borisy, AL Hopkins, André C Müller, B Benassi, B Luo, B Palsson, BJ Druker, C Pan, CA Eide, CI Bliss, CL Sawyers, D Bixby, F Grebien, Florian Grebien, Florian P Breitwieser, Forest M White, FP Breitwieser, FX Mahon, G Dennis Jr., Georg E Winter, Giulio Superti-Furga, H Kitano, IJ Griswold, J Dopazo, J Lamb, J Lehár, J Zhang, Jacques Colinge, JE Cortes, JE Delmore, Karoline V Gleixner, Keiryn L Bennett, LM Packer, M Albajar, M Azam, M Schuhmacher, Manuela Gridling, Martin Bilban, ME Gorre, N Meyer, NJ Donato, O Hantschel, P Filippakopoulos, Peter Valent, PL Ross, S Adhikary, S Gupta, S Pelengaris, Scott M Carlson, SR Hann, T O′Hare, U Rix, U Rix, Uwe Rix, X Chen, ZA Knight   +58 more
core   +1 more source

Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. [PDF]

, 2010
PURPOSE: Dasatinib is a dual Src/Abl inhibitor recently approved for Bcr-Abl+ leukemias with resistance or intolerance to prior therapy. Because Src kinases contribute to multiple blood cell functions by triggering a variety of signaling pathways, we ...
Arceci, Robert, Blanchard, Elisabeth G, Cayre, Yvon E, Corey, Seth J, Futami, Muneyoshi, Guerrouahen, Bella S, Kanerva, Jukka, Kornblau, Steven M, Lee, Francis Y, Nwawka, Kenechi, Robinson, Lisa J, Vaklavas, Christos, Whichard, Zakary L, Wieder, Eric   +13 more
core   +1 more source

ACCUMULATED LABORATORY DATA IN B12 VITAMIN BLOOD LEVEL TIME DEPENDENCY STUDIES IN PATIENTS WITH MYELOMA, LYMPHOCYTIC LEUKEMIA AND MYELOBLASTIC LEUKEMIA IN LATVIA [PDF]

, 2023
Vitamin B12 blood level in patients with myeloma (C90 - International Classification of Diseases (ICD-10)), lymphocytic leukemia (C91) and myeloblastic leukemia (C92) prior and after the diagnosis and also BCR-ABL (fusion gene from breakpoint cluster ...
Auce, Agris, Gavars, Didzis, Miķelsone, Agnese, Tauckels, Ēriks, Tutane, Anna Inese   +4 more
core   +3 more sources

Understanding resistance to combination chemotherapy [PDF]

, 2012
available in PMC 2014 April 04The current clinical application of combination chemotherapy is guided by a historically successful set of practices that were developed by basic and clinical researchers 50–60 years ago.
Hemann, Michael, Lauffenburger, Douglas A., Pritchard, Justin R.   +2 more
core   +1 more source

Knocking down low molecular weight protein tyrosine phosphatase (LMW-PTP) reverts chemoresistance through inactivation of Src and Bcr-Abl proteins.

PLoS ONE, 2012
The development of multidrug resistance (MDR) limits the efficacy of continuous chemotherapeutic treatment in chronic myelogenous leukemia (CML). Low molecular weight protein tyrosine phosphatase (LMW-PTP) is up-regulated in several cancers and has been ...
Paula A Ferreira, Roberta R Ruela-de-Sousa, Karla C S Queiroz, Ana Carolina S Souza, Renato Milani, Ronaldo Aloise Pilli, Maikel P Peppelenbosch, Jeroen den Hertog, Carmen V Ferreira   +8 more
doaj   +1 more source

THE ANTINEOPLASTIC ROLE OF STAT5 INHIBITION IN BCRABL1-POSITIVE CELLS EXPOSED TO PIMOZIDE ALONE AND IN COMBINATION WITH DASATINIB AND PONATINIB [PDF]

, 2021
EVEN though the last decades have seen the success of the targeted treatments for BCRABL1-positive Chronic Myeloid Leukemia (CML), with the outstanding achievement of placing selected patients into the so called treatment-free remission, a minor part of ...
SANTORO, Marco
core